Sinopharm Group Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Wanyong Lian
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | less than a year |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 3.7yrs |
| Gemiddelde ambtstermijn bestuur | 4.2yrs |
Recente managementupdates
Recent updates
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05CEO
Wanyong Lian (53 yo)
less than a year
Tenure
Mr. Wanyong Lian has been the Head of the investment management department of CNPGC since February 2008. Mr. Lian has over 20 years of working experience, all of which is management experience. Mr. Lian wa...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President & Executive Director | less than a year | geen gegevens | geen gegevens | |
| Chief Financial Officer | 3.7yrs | geen gegevens | geen gegevens | |
| Secretary to the Board | 5.9yrs | geen gegevens | geen gegevens |
3.7yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 1099 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President & Executive Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Vice Chairman | 14.5yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | 3.4yrs | geen gegevens | geen gegevens | |
| Chief Supervisor | 3.4yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 4.2yrs | CN¥350.00k | geen gegevens | |
| Independent Non-Executive Director | 4.2yrs | CN¥350.00k | geen gegevens | |
| Non-Executive Chairman | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Director | 7.2yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 5.9yrs | CN¥350.00k | geen gegevens | |
| Non Executive Director | 4.4yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 4.2yrs | CN¥350.00k | geen gegevens | |
| Non-executive Director | 1.2yrs | geen gegevens | geen gegevens |
4.2yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 1099 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).